The clinical trial FLAURARE is an international, multicenter, open-label Phase II study evaluating the combination of Osimertinib plus platinum-based chemotherapy (carboplatin or cisplatin plus pemetrexed) as first-line therapy in patients with stage IV non–small cell lung cancer (NSCLC) harboring uncommon EGFR mutations. The primary objective is to assess the efficacy of the combination treatment. Key inclusion criteria include histologically or cytologically confirmed metastatic adenocarcinoma NSCLC, untreated metastatic disease, presence of one or more EGFR mutations in exons 18–21 excluding common mutations (exon 19 deletion, L858R, exon 20 insertion, T790M), confirmed EGFR status, ECOG performance status = 1, at least one measurable lesion per RECIST v1.1, and adequate organ function. All participants receive Osimertinib plus chemotherapy in a single-arm design. Secondary endpoints include safety, tolerability, and patient-reported quality of life.
This study investigates whether combining Osimertinib with chemotherapy is effective and tolerable in adults with advanced non-small cell lung cancer (NSCLC) carrying uncommon EGFR mutations. The goal is to assess treatment efficacy and safety in patients who have not yet received systemic therapy for metastatic disease. The atypical EGFR mutation status is confirmed before treatment. All participants receive the combination of Osimertinib plus standard platinum-based chemotherapy. In addition, the study monitors treatment side effects and quality of life.
